Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

PharmaJet spotlights Nature publication on Stratis IM System benefits

Closely held PharmaJet has announced that the peer-reviewed journal Nature has published findings from a U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Phase 1 trial, demonstrating that the...

December 10, 2024

Developments

Akoya and NeraCare enter agreement to develop and commercialize Immunoprint test for melanoma

Akoya Biosciences (NASDAQ:AKYA) announced that it has entered into an exclusive global licencing agreement with NeraCare to develop and commercialize NeraCare’s Immunoprint test for guiding early-stage melanoma...

December 10, 2024

Developments

IN8bio reports sustained PFS in INB-100 trial for HSCT patients

IN8bio (NASDAQ:INAB) shared updated data showcasing continued progression-free survival (PFS) from its Phase 1 trial of INB-100 in older patients with hematologic malignancies undergoing haploidentical stem cell...

December 10, 2024

Developments

Profound Medical gains media attention for its incision- and radiation-free TULSA treatment for prostate cancer and/or BPH

Profound Medical’s (NASDAQ:PROF; TSX:PRN) CEO, Arun Menawat, recently sat down with Fierce Biotech to discuss how TULSA-PRO is revolutionizing prostate disease treatment. In the interview, Dr. Menawat noted...

December 9, 2024

Developments

Immunovia announces positive results and strong accuracy of next-gen test for PDAC

Immunovia (STO:IMMNOV) has announced the completion of its CLARITI study, demonstrating positive outcomes and strong accuracy in the clinical validation of its next-generation test for the early detection of pancreatic...

December 9, 2024

Developments

BioNxt achieves milestones for BNT23001 in MS

BioNxt Solutions (CSE:BNXT; OTC PINK:BNXTF; FSE:BXT) has announced that key milestones have been achieved in the development of BNT23001 for the treatment of multiple sclerosis (MS). BNT23001 is BioNxt’s proprietary...

December 9, 2024

Developments

Innate to receive up to $7.9 million from IFLI to advance IPH6501 in FL

Innate Pharma (Euronext Paris:IPH; NASDAQ:IPHA) and the Institute for Follicular Lymphoma (IFLI) have announced a collaboration agreement to clinically evaluate the potential of Innate’s IPH6501 in follicular lymphoma...

December 6, 2024

Developments

FDA grants clearance for Nanox.ARC expanding application to pulmonary and general use

Nanox Imaging (NASDAQ:NNOX) has announced that its Nanox.ARC stationary X-ray system has received 510(k) clearance from the FDA, allowing general use including the human musculoskeletal system, pulmonary, intra...

December 6, 2024

Developments

FDA grants RMAT for combination of Affimed’s acimtamig and Artiva’s AlloNK

Affimed (NASDAQ:AFMD) announced that the FDA has granted regenerative medicine advanced therapy (RMAT) designation to its combination therapy involving Affimed’s innate cell engager (ICE) acimtamig, and Artiva...

December 5, 2024

Developments

Nkarta receives IND clearance for IST in MG; launches enrollment of Ntrust-2 trial

Nkarta (NASDQ:NKTX) announced the clearance of an investigational new drug clearance (IND) application for its investigator-sponsored trial (IST) evaluating NKX019 in patients with myasthenia gravis (MG), alongside the...

December 5, 2024

Developments

Cartesian reports promising results from Phase 2b trial of Descartes-08 in MG

Cartesian Therapeutics (NASDAQ:RNAC) announced updated efficacy and safety data from its Phase 2b trial of Descartes-08 in myasthenia gravis (MG), showing deep, durable responses without the need for chemotherapy. The...

December 4, 2024

Executive Moves

Outlook’s CEO steps down; Lawrence Kenyon named interim CEO

Outlook Therapeutics (NASDAQ:OTLK) has appointed Lawrence Kenyon, EVP, CFO, and board member, as interim CEO, effective immediately. Russell Trenary has stepped down as the company’s president and CEO. Mr. Kenyon has...

December 4, 2024

Subscribe